Skip to main content
. Author manuscript; available in PMC: 2025 Jan 1.
Published in final edited form as: HLA. 2023 Oct 18;103(1):e15251. doi: 10.1111/tan.15251

Table 5.

KIR + ligand combinations associating with severe COVID-19

Receptor + ligand
combination		 Non-hospitalized
N=402		 Hospitalized
N=1569
f (%) f (%) OR CI (95%) p
KIR2DS4*001
2DS4*00101 + ligand 73 (18.2%) 374 (23.8%) 1.41 1.04-1.91 0.028
2DS4*00101 + no ligand 40 (10.0%) 198 (12.6%) 1.35 0.92-2.01 0.133
KIR2DS1-4 + HLA ligands
Absent or 1 pair 357 (88.8%) 1278 (81.5%) Ref
2 to 4 pairs 45 (11.2%) 291 (18.5%) 1.94 1.36-2.80 3.1x10 −04

By logistic regression association analysis, using sex and age >60 years old as covariates. f: carrier frequency. Ref: Allotype of reference, OR: odds ratio, CI: confidence interval. In bold p-values < 0.05. No p-value correction applied. HLA ligands for respective KIR are given in Methods.